Understanding Body Protection Compound 157: a synthetic 15-amino-acid peptide derived from a fragment of human gastric juice protein.

Overview

BPC-157 (short for Body Protection Compound 157), a 15-amino-acid synthetic peptide modeled on a sequence first identified in human gastric juice, sits at an unusual moment. The U.S. Food and Drug Administration (FDA) has never approved it for any human use. In 2023, the agency placed it in Category 2, the bucket reserved for bulk substances flagged as posing "significant safety risks" if compounded by a pharmacy and dispensed to a patient. [STAT 2/3/26; Undark 2/3/26; FDA] On July 23, 2026, the Pharmacy Compounding Advisory Committee (PCAC) voted 8-6, with one abstention, to recommend adding BPC-157 free base and acetate to the 503A Bulks List. FDA staff had recommended against inclusion, and the committee's recommendation is non-binding — FDA has not taken final action. [FDA; FDA 7/23-24/26 PCAC; Reuters 7/23/26]

The science underneath all of that is far narrower than the conversation around it suggests. Roughly 200 BPC-157 papers are indexed on PubMed and, in a peculiar twist, almost every one lists the same primary author: Predrag Sikiric of the University of Zagreb in Croatia (or Sven Seiwerth, a close colleague). The vast majority of that work was conducted not in humans but in rodents. [Undark 2/3/26; STAT 2/3/26] An investigation by science publication Undark revealed undisclosed financial ties between Sikiric and BPC-157-related patents and companies; STAT News and Scientific American have separately characterized the human evidence base as "small pilot studies" and the broader literature as thin. [Undark 2/3/26; STAT 2/3/26; Sci. Am. 4/18/26]

What it is

BPC-157 (short for Body Protection Compound 157) is a synthetic 15-amino-acid peptide. The sequence on which it was modeled came from human gastric juice, and the earliest animal experiments described it as having broad protective effects across multiple tissue types: stomach lining, tendons, ligaments, and blood vessels. [STAT 2/3/26; Undark 2/3/26; Sci. Am. 4/18/26] The earliest PubMed entry tied to the compound is a 1992 paper authored by a Croatian researcher, Predrag Sikiric, and 17 colleagues who reported "a new potent peptide" isolated from gastric juice. [Undark 2/3/26]

How it's proposed to work

As described in the available preclinical literature — almost all of it in rodents — BPC-157 acts on several overlapping cellular pathways: angiogenesis (the body's process for forming new blood vessels), cell growth, soft-tissue repair, and inflammation. In animal models, researchers have reported that the peptide encourages new blood vessel formation and tamps down inflammatory signaling, with downstream effects on how tendons, ligaments, and muscles repair after injury. [Sci. Am. 4/18/26; Undark 2/3/26; McGuire et al. 2025; Hsieh et al. 2020; Gwyer et al. 2019; Vasireddi et al. 2025; AOSSM Spring 2026]

Common forms in circulation

Subcutaneous injection: the most common form in wellness clinics, medspas, and influencer settings [Sci. Am. 4/18/26; STAT 2/3/26; Gothamist 4/23/26]
Oral capsule: the form tested in a canceled 2015 Phase I trial [STAT 2/3/26; Undark 2/3/26]
Enema: the delivery used in the Croatian PLIVA ulcerative colitis trials of the 2000s; the resulting papers have not been published and are not indexed in PubMed [Undark 2/3/26]

Names and aliases

BPC-157, BPC 157, PL 14736 (legacy alias) [Undark 2/3/26; STAT 2/3/26]
The "Wolverine stack": BPC-157 paired with TB-500 [Sci. Am. 4/18/26; STAT 4/6/26]
"Glow stack"/"KLOW": BPC-157 + TB-500 + GHK-Cu (± KPV); increasingly marketed as luxury wellness supplements at certain medical spas in major cities [Sci. Am. 4/18/26; Gothamist 4/23/26]

Regulatory status

BPC-157 has no FDA-approved indication for use in humans anywhere in the United States, and never has in its history. FDA's compounding safety page currently lists BPC-157 under "bulk drug substances nominated but withdrawn," rather than in the active Category 2 table, and continues to flag potential immunogenicity for certain routes, peptide-related impurities and API-characterization complexity, and limited safety information for the proposed routes. This procedural placement does not equal FDA approval or current authorization to compound. In 2023, the FDA removed 19 peptides from the list of substances pharmacies were permitted to compound. BPC-157 was on that list, in company with GHK-Cu, KPV, and ipamorelin. [FDA; STAT 4/15/26; BioPharma Dive 4/16/26]

On July 23, 2026, the Pharmacy Compounding Advisory Committee met to reconsider BPC-157 free base and acetate for potential inclusion on the 503A Bulks List, evaluating the substances for ulcerative colitis. FDA staff had recommended against inclusion, concluding that the substances were not well characterized, historical compounding use was unclear, the available evidence was insufficient to support effectiveness for ulcerative colitis, and safety and immunogenicity information was inadequate. The committee nonetheless voted 8-6, with one abstention, to recommend adding both forms to the 503A Bulks List. [FDA BPC-157 briefing document; FDA 7/23-24/26 PCAC; Reuters 7/23/26]

The recommendation is advisory only: FDA has not added BPC-157 to the 503A Bulks List, and the vote does not itself authorize compounding, establish safety or efficacy, or constitute FDA approval. A regulatory recommendation is not a scientific finding, and the underlying evidence gaps described throughout this page do not change because of the vote. [FDA BPC-157 briefing document; FDA 7/23-24/26 PCAC]

Purported benefits, by evidence strength

Benefit category	Tier	What the reporting actually says	Source
Tendon, ligament, and muscle repair	Animal model	Reported to enhance healing in rodents; promotes angiogenesis and reduces inflammation in animal studies. Human data: limited; no replicated, peer-reviewed efficacy trial in human findings.	[STAT 2/3/26; Sci. Am. 4/18/26; Undark 2/3/26]
Gastric ulcer/GI mucosal protection	Animal model	Original 1992 description framed BPC-157 as a "protective compound" from gastric juice; rodent ulcer studies are the historical backbone of the literature.	[Undark 2/3/26; STAT 2/3/26]
Ulcerative colitis (enema formulation)	Clinical trial (Croatian PLIVA, 2000s)	Tested in two clinical trials by the Croatian pharmaceutical company PLIVA; resulting papers have not been published to date and are not indexed in PubMed. FDA's 2026 review separately found the available ulcerative-colitis evidence insufficient to support effectiveness.	[Undark 2/3/26; FDA BPC-157 briefing document]
Anti-inflammatory effects (broad)	Animal model / mechanistic hypothesis	Described in reviews as plausible based on rodent work and proposed pathways; not established in humans.	[Sci. Am. 4/18/26; STAT 2/3/26]
Recovery from injury or workout	Anecdotal/community reported	Reported by influencers and patients in podcast and social media settings. Not supported by replicated, peer-reviewed human efficacy data.	[Sci. Am. 4/18/26; STAT 4/6/26]
Dry eye, anti-tumor potential	Mechanistic hypothesis only	Mentioned in reporting as among the claims attached to the literature, but not as established. Anti-tumor language coexists in the literature with separate concerns about pro-angiogenic effects supporting tumor growth.	[STAT 2/3/26]
Anti-aging/longevity	Anecdotal only	Surfaces in influencer and clinic marketing; no clinical evidence.	[Sci. Am. 4/18/26; STAT 4/6/26]

What the evidence base looks like

Three things are worth knowing up front about the BPC-157 evidence base:

The corpus is large but unusually concentrated. Roughly 200 BPC-157 papers are indexed on PubMed, and the vast majority list either Predrag Sikiric or his colleague, Sven Seiwerth, as a main author. A 2025 commentary by Józwiak and colleagues in the peer-reviewed journal Pharmaceuticals quantifies this figure directly: more than 80% of all PubMed and Google Scholar records under "BPC 157" trace to that single research group. [Undark 2/3/26; STAT 2/3/26; McGill 3/13/26; Józwiak et al. 2025; Vasireddi et al. 2025]

Human data are minimal. The reporting consistently summarizes the human BPC-157 evidence as three studies: a Phase I safety trial of 42 healthy volunteers, registered in 2015, canceled in 2016, and never published; a small retrospective case series of 12 knee-pain patients with no control group and no validated outcome measure; and a 2025 pilot safety study involving two healthy adults. [STAT 2/3/26; Undark 2/3/26; NPR 2/23/26; Vox 4/23/26; McGuire et al. 2025; Vasireddi et al. 2025; AOSSM Spring 2026; BBC Sci. Focus 3/31/26]

Conflict-of-interest disclosures are, in places, missing. Undark's reporting identified Sikiric as a named inventor on BPC-157-related patent applications dating back to at least 1989; as CEO of Diagen, a Croatian company that says it owns a patent for a "special stable version" of BPC-157; and as a recorded owner of PharmaCotherapia, the company that sponsored a small Tijuana trial. None of those ties appeared in any of the published papers Undark reviewed. [Undark 2/3/26]

Key literature

Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals. 2025;18(10):1451. Independent peer-reviewed quantification of the single-lab concern: more than 80% of all PubMed and Google Scholar records under "BPC 157" are linked to the Sikiric group. The often-repeated "anti-tumor potential" claim is not supported by any published in vivo tumor-growth or metastasis study.

McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. Confirms the molecular pathways most often invoked for BPC-157 (VEGFR2; Akt/eNOS; ERK1/2; angiogenesis; fibroblast activity; anti-inflammatory effects), and concludes only three pilot human studies exist: "until well-designed clinical trials are conducted, BPC-157 should be considered investigational, and its use approached with caution."

Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025. Claims about BPC-157 in athletes outpace the human evidence; existing data are largely preclinical, animal-model, and dominated by a narrow corpus of investigators.

Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153–159. Reports that existing studies have been "consistently positive" for tendon, ligament, and skeletal-muscle healing in animal models.

Hsieh MJ, Lee CH, Chueh HY, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10:17078. Independent mechanistic study in isolated rat aorta showing concentration-dependent, endothelium-dependent vasodilation mediated by nitric oxide.

References

STAT News, Feb. 3, 2026 — "BPC-157: The peptide with big claims and scant evidence"
Undark, Feb. 3, 2026 — "BPC-157: A MAHA-Adjacent Peptide, Linked to Croatia"
FDA — "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks"
FDA — Evaluation of BPC-157-Related Bulk Drug Substances for Inclusion on the 503A Bulk Drug Substances List. Pharmacy Compounding Advisory Committee briefing document. May 11, 2026.
Reuters, July 23, 2026 — "FDA panel votes to place popular peptide BPC-157 on compounding list"
STAT News, Apr. 15, 2026 — "FDA peptide advisers expected to support RFK Jr.'s legalization push"
BioPharma Dive, Apr. 16, 2026 — "FDA moves toward easing restrictions on certain peptides"
Scientific American, Apr. 18, 2026 — "The science behind the peptide craze"
NPR, Feb. 23, 2026 — "Influencers are promoting peptides for better health. What does the science say?"
McGill Office for Science and Society, Mar. 13, 2026 — "BPC-157 — No Proof Required!"
Vox, Apr. 23, 2026 — "Please don't inject yourself with bootleg peptides"
American Orthopaedic Society for Sports Medicine, Spring 2026 issue — "The Boom of Peptides in Sports Medicine: Do We Know Anything More?"
BBC Science Focus, Mar. 31, 2026 — "Most anti-ageing peptides don't work. But these might"
Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Reply to Sikiric et al. Pharmaceuticals. 2025;18(10):1451.
McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? Curr Rev Musculoskelet Med. 2025.
Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. HSS Journal. 2025.
Gwyer D, Wragg NM, Wilson SL. Cell Tissue Res. 2019;377(2):153–159.
Hsieh MJ, Lee CH, Chueh HY, et al. Sci Rep. 2020;10:17078.

BPC-157